Usefulness of uric acid-to-high-density lipoprotein cholesterol ratio for the evaluation of insulin resistance in healthy normoglycaemic and normoinsulinaemic men
Experimental and Clinical Endocrinology & Diabetes · 2026-01 · 134 (01) · 4-9
DOI: 10.1055/a-2778-0665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, online erschienen am 11.02.2026. Verfasst von Anastasiya M Kaneva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of ecological and medical physiology, Institute of Physiology of Komi Science Centre of the Ural Branch of the Russian Academy of Sciences…. Hauptthemen laut MEDLINE: Insulin Resistance, Uric Acid, Cholesterol, HDL. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Institute of Physiology of Коmi Science Centre of the Ural Branch of the Russian Academy of Sciences, FRC Komi SC UB RAS.
Abstract (Originalsprache)
Uric acid-to-high-density lipoprotein cholesterol ratio (UHR) is a novel and promising marker for metabolic abnormalities. Recent studies have demonstrated that UHR is related to a number of diseases that are caused by insulin resistance. However, only a few studies have investigated the association between UHR and insulin resistance. The aim of this study was to evaluate the diagnostic ability of UHR to detect insulin resistance in healthy normoglycaemic and normoinsulinaemic men. A total of 209 healthy men (aged 23–57 years) with normoglycaemia and normoinsulinaemia were included in this study. Anthropometric and biochemical data were collected. Insulin resistance was assessed by original homeostasis model assessment of insulin resistance (HOMA-IR) and its computerized updated version (HOMA2-IR), the fasting glucose/insulin ratio (FGIR), the McAuley index, and the triglyceride-glucose (TyG) index. A receiver operating characteristic (ROC) curve analysis was conducted to evaluate the ability of UHR to predict insulin resistance. UHR was significantly correlated with HOMA-IR (rs=0.23; p=0.001) and HOMA2-IR (rs=0.20; p=0.003). There were no correlations between UHR and other insulin resistance indices. The prevalence of insulin resistance among the participants was 21.5% and 9.6% according to HOMA-IR (>2.7) and HOMA2-IR (>1.8) cut-off values, respectively. ROC curve analysis revealed the diagnostic ability of UHR to determine insulin resistance assessed by HOMA2-IR (area under the ROC (AUROC) curve: 0.680; p=0.005). However, UHR did not predict insulin resistance assessed by HOMA-IR (AUROC curve: 0.584; p=0.087). UHR is not a reliable marker of insulin resistance in healthy men with normoglycaemia and normoinsulinaemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of ecological and medical physiology, Institute of Physiology of Komi Science Centre of the Ural Branch of the Russian Academy of Sciences, FRC Komi SC UB RAS, Syktyvkar, Russian Federation.
ORCID-Profile: Anastasiya M Kaneva
Förderung
- Institute of Physiology of Коmi Science Centre of the Ural Branch of the Russian Academy of Sciences, FRC Komi SC UB RAS
Zitieren
APA
Kaneva, A. M., & Bojko, E. R. (2026). Usefulness of uric acid-to-high-density lipoprotein cholesterol ratio for the evaluation of insulin resistance in healthy normoglycaemic and normoinsulinaemic men. Experimental and Clinical Endocrinology & Diabetes, 134(01), 4-9. https://doi.org/10.1055/a-2778-0665
Vancouver
Kaneva AM, Bojko ER. Usefulness of uric acid-to-high-density lipoprotein cholesterol ratio for the evaluation of insulin resistance in healthy normoglycaemic and normoinsulinaemic men. Experimental and Clinical Endocrinology & Diabetes. 2026;134(01):4-9. doi:10.1055/a-2778-0665
BibTeX
@article{Kaneva2026,
author = {Kaneva, Anastasiya M and Bojko, Evgeny R},
title = {Usefulness of uric acid-to-high-density lipoprotein cholesterol ratio for the evaluation of insulin resistance in healthy normoglycaemic and normoinsulinaemic men},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2026},
volume = {134},
number = {01},
pages = {4--9},
doi = {10.1055/a-2778-0665}
}
EUVIMED